

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gentz et al

Application Serial No.: 09/518,931

Group Art Unit: 1632

Filed: March 3, 2000

Examiner: Not assigned

Title: Tumor Necrosis Factor
Receptors 6alpha and 6beta

Attorney Docket No.: PF454P1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AN listed on the attached revised Form PTO/SB/08. Copies of references AA-AN are enclosed herewith.

References AE-AF and AM were cited in an International Search Report (AN) issued in a foreign counterpart of the instant application.

In addition, Applicants wish to bring to the attention of the Examiner that SEQ ID NOS:1, 3 and 17, and the cDNA clones HPHA52 and HTPCH84 of the present invention are related to SEQ ID NO:3916 disclosed in U.S. Application No. 08/803,610. SEQ ID NOS:1, 3 and 18, and the cDNA clones HPHA52 and HTPCH84 of the present invention are related to SEQ ID NO:4095 disclosed in U.S. Application No. 08/276,163. SEQ ID NOS:1 and 3, and the cDNA clones HPHA52 and HTPCH84 of the present invention are related to SEQ ID NO:11,030 disclosed in U.S. Application No. 08/346,731.

Applicants respectfully request that the Examiner review the materials and information identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since it is believed this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted

Date: OCTOBER 25, 2000


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

Enclosure